Solara Active Pharma Sciences Ltd (SOLARA)

Healthcare · Pharmaceuticals · NSE · Updated 17 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹710.1 ↑ 4.59% (1Y)

🎯 Key Takeaways

Solara Active Pharma Sciences is transitioning from a distressed, loss-making profile to a stabilized growth trajectory, marked by consistent top-line expansion, margin improvement, and active debt reduction. The company has shifted focus from survival to operational efficiency and strategic capacity enhancement, signaling a turnaround phase anchored in base business resilience despite external headwinds.
Revenue declined 1.5% QoQ to ₹382 in Q1FY27.
⚠️ Ibuprofen business continues to generate EBITDA losses, and the strategic review outcome remains uncertain, posing a potential drag on overall profita

Market Cap

₹3,426

P/B Ratio

2.73

ROE

-0.1%

ROCE

4.7%

Debt/Equity

0.53

Promoter

41.9%

✨ Ask AI About SOLARA 📊 Interactive Charts

📖 The Story

Solara Active Pharma Sciences is transitioning from a distressed, loss-making profile to a stabilized growth trajectory, marked by consistent top-line expansion, margin improvement, and active debt reduction. The company has shifted focus from survival to operational efficiency and strategic capacity enhancement, signaling a turnaround phase anchored in base business resilience despite external headwinds.

📰 What's Happening

In Q1 FY27, Solara delivered 20% YoY revenue growth to ₹384 crores and 55% YoY PAT growth to ₹16.3 crores, driven by 24% growth in base business revenue. Management highlighted ongoing strategic review of the Ibuprofen business to address persistent losses, targeting quarterly EBITDA losses of -₹15 crores. A key development was the board's approval of ₹55-60 crores in FY27 capex focused on debottlenecking and brownfield expansion to increase capacity for high-margin products by 20-30%. Concurrently, net debt declined by 22% YoY to ₹479 crores, supporting a healthier balance sheet. The company also completed the conversion of rights shares and small ESOP allotments, marginally diluting shareholders but reinforcing governance discipline. These actions reflect a deliberate pivot toward sustainable growth, margin discipline, and capital efficiency.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	314	349	387	382
Operating Profit	10	12	32	35
OPM %	3.3%	3.4%	8.2%	9.2%
Net Profit	-10	-17	10	16
EPS	₹-2.36	₹-3.98	₹2.20	₹3.52

The company's financial trajectory shows a clear inflection: after two consecutive quarters of revenue contraction and losses in Dec 2025 and Sep 2025, Solara reversed course with sequential and YoY improvements in revenue, operating profit, and PAT. Q1 FY27 marks the third straight quarter of growth, with revenue rising from ₹314 crores (Sep 2025) to ₹382 crores (Jun 2026), and PAT turning positive at ₹16 crores. This recovery is underpinned by base business momentum, with revenue growth accelerating to 24% YoY. Despite margin pressure from commodity Ibuprofen, the core business is gaining traction, supported by operational upgrades and cost management. The shift from negative to positive operating and net income trends underscores a fundamental improvement in execution and demand.

🔮 Management Outlook & What's Next

Management has reaffirmed its commitment to 10% growth in base business revenue and targeted EBITDA margins of 25%±1% for this segment. It aims to reduce net debt to sub-INR450 crores by March 2027, reflecting a disciplined capital allocation strategy. The ongoing strategic review of the Ibuprofen business, with a target to limit quarterly EBITDA losses to -₹15 crores, indicates a focus on rationalizing underperforming assets. Expansion plans via debottlenecking and brownfield capex are designed to scale high-margin offerings, suggesting confidence in sustainable profitability. These priorities signal a shift toward long-term value creation, with an emphasis on operational resilience and margin stability amid raw material volatility.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	40	40	44	45
Reserves	1,046	1,054	1,210	1,208
Borrowings	840	796	646	665
Total Liabilities	2,290	2,232	2,293	2,333
Fixed Assets	830	799	843	1,238
Investments	2	2	2	5
Total Assets	2,290	2,232	2,293	2,333

The balance sheet reflects a company actively deleveraging and strengthening its financial foundation. Net debt fell by 22% YoY to ₹479 crores by end of Q1 FY27, with management targeting sub-INR450 crores by March 2027. Borrowings declined marginally from ₹796 crores (Mar 2025) to ₹665 crores (Mar 2026), while equity and reserves remained stable. This reduction is not driven by asset sales but by operational cash flow and prudent financial management. With total assets growing steadily and equity base expanding slightly, the company is improving its debt-to-equity ratio and interest coverage, supporting greater financial flexibility. The focus on debt reduction aligns with broader strategic goals of reducing risk and enabling future investments without overleveraging.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025	Mar 2026
Operating	+213	+153
Investing	-37	-99
Financing	-180	-54
Net Cash Flow	-4	+1

👥 Shareholding Pattern

Category	Q3FY26	Q4FY26	Q1FY27
Promoters	42.0%	42.0%	41.9%
FII	12.0%	11.6%	11.5%
DII	3.6%	3.8%	3.7%
Public	24.6%	25.0%	25.8%
# Shareholders	71,920	70,400	70,490

Shareholding patterns show stable promoter holding at ~42% over the last three quarters, indicating confidence in long-term prospects. Foreign Institutional Investors (FII) have slightly increased their stake from 11.59% (Q4FY26) to 11.52% (Q1FY27), while Domestic Institutional Investors (DII) remained flat at ~3.75%. The number of public shareholders has marginally grown, suggesting retail interest is holding steady. No significant dilution from institutional exits or promoter sales is evident. The modest ESOP issuance caused a minimal increase in paid-up capital, with no material impact on ownership structure. Overall, the shareholder base remains stable, with no signs of large-scale institutional exit or activist pressure.

⚖️ Peer Comparison — Pharmaceuticals

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
SUNPHARMA	4.45 L Cr	36.8	18.7%	14.6%	0.05
DIVISLAB	2.44 L Cr	83.5	23.0%	17.4%	0.00
TORNTPHARM	1.83 L Cr	76.9	15.1%	25.7%	1.76
ZYDUSLIFE	1.10 L Cr	24.6	16.8%	16.6%	0.43
CIPLA	1.10 L Cr	32.6	13.2%	9.8%	0.01
LAURUSLABS	1.03 L Cr	94.1	20.8%	20.6%	0.45
DRREDDY	95,591	29.6	10.1%	8.4%	0.17
AUROPHARMA	94,420	25.6	12.8%	9.8%	0.20
LUPIN	93,605	16.5	27.9%	24.7%	0.26
MANKIND	92,842	45.4	13.9%	12.7%	0.38

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM ZYDUSLIFE CIPLA

⚠️ Risk Factors

1. Ibuprofen business continues to generate EBITDA losses, and the strategic review outcome remains uncertain, posing a potential drag on overall profitability. 2. Raw material cost inflation from West Asia could pressure gross margins if cost pass-through mechanisms fail to keep pace. 3. Capex execution delays or cost overruns in brownfield expansion could impact timelines for capacity gains and margin improvement. 4. Despite debt reduction, net leverage remains elevated relative to peers, and any slowdown in revenue momentum could strain financial flexibility. These factors require close monitoring as the company transitions from stabilization to growth.

📋 Recent Filings

🧠 Analyst's Read

Solara Active Pharma is executing a credible turnaround, with base business growth and debt reduction supporting a foundation for sustainable profitability. The strategic focus on capacity expansion and margin discipline offers upside, but the success hinges on the Ibuprofen review outcome and margin resilience amid input cost volatility. Investors should watch for clarity on Ibuprofen's fate and execution of capex plans in the coming quarters.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on SOLARA

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SOLARA files new disclosures

Track SOLARA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SOLARA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd